Poor efficacy of amphotericin B-based therapy in CNS aspergillosis

Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Elizabeth Reed, Peter Troke, Eckhard Thiel

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


Summary Recently, improved response and survival rates in patients treated with voriconazole and neurosurgery for central nervous system (CNS) aspergillosis have been reported. We assessed retrospectively the outcome in 17 patients with definite or probable CNS aspergillosis treated with amphotericin B alone (n = 15) or in combination with 5-fluorocytosine (n = 3) or itraconazole (n = 2). Four patients underwent neurosurgery. The mortality rate was 100% with a median survival of only 10 days (range: 3-60) after onset of first symptoms or first radiological evidence of CNS aspergillosis. In conclusion, treatment with amphotericin B and itraconazole has negligible efficacy in CNS aspergillosis.

Original languageEnglish (US)
Pages (from-to)196-200
Number of pages5
Issue number3
StatePublished - May 2007


  • Amphotericin B
  • Central nervous system aspergillosis
  • Itraconazole
  • Neuroaspergillosis

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases


Dive into the research topics of 'Poor efficacy of amphotericin B-based therapy in CNS aspergillosis'. Together they form a unique fingerprint.

Cite this